the aid library

LIST OPTIONS

Filter

12648

Sort by:

Direction:

Download (47)

View PDF (63)

Toolkit for developing a multisectoral action plan for noncommunicable diseases: module 5: evaluating the implementation of a multisectoral action plan

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

Key stakeholders must be involved in the planning, implementation, monitoring and evaluation of NCD plans and programmes. Within a ministry of health there will be different types of stakeholders, such as programme managers and senior managers in departments of prevention, health promotion, and hosp... more

Download (46)

View PDF (45)

Sustainable management of radiotherapy facilities and equipment

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The document, "Sustainable Management of Radiotherapy Facilities and Equipment," by WHO and IAEA, provides guidelines for managing radiotherapy equipment and facilities to ensure effective and safe cancer treatment. It covers essential aspects like preventive and corrective maintenance, funding, inf... more

Download (50)

View PDF (51)

Childhood respiratory disease linked to the enviroment

World Health Organization WHO (2009) CC2

Childhood Respiratory Diseases & the Environment learning objectives •To understand how the respiratory tract is affected by the environment •To describe respiratory diseases linked to the environment •To list one population-level intervention and one personal-level intervention for d... more

Download (142)

View PDF (143)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (159)

View PDF (172)

Psychological interventions implementation manual: Integrating evidence-based psychological interventions into existing services

World Health Organization WHO (2024) C_WHO

Evidence-based psychological interventions are an important part of health, social, protection and education services and can help increase access to effective mental health treatments and progression towards universal health coverage. This manual provides managers and others responsible for plan... more

Download (120)

View PDF (124)

G20 Shared Understanding on the Importance of UHC Financing in Developing Countries: Towards Sustainable and Inclusive Growth

G20 Health and Finance Ministers G20 (2019) CC

As a deliverable of the G20 Health and Finance Ministers' Meeting on June 28, 2019, ministers confirmed their commitment to this "G20 Shared Understanding."

Download (109)

View PDF (119)

Audited Financial Statements for the year ended 31 December 2020

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

WHO’s total revenue in 2020 was US$ 4299 million and total expenses were US$ 3561 million, resulting in a surplus of US$ 824 million, which includes finance revenue (e.g. interest and investment income) of US$ 86 million, representing increases of 38% and 15% in revenue and expenses respectively. ... more

Download (165)

View PDF (325)

Guidelines for drinking-water quality: Small water supplies

World Health Organization WHO (2024) C_WHO

Small drinking-water supplies commonly experience operational, managerial, technical and resourcing challenges that impact their ability to deliver safe and reliable services. The needs and opportunities associated with these supplies therefore warrant explicit consideration in policies and regulati... more

Download (295)

View PDF (393)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (165)

View PDF (176)

Pre-referral treatment with rectal artesunate of children with suspected severe malaria: a field guide

World Health Organization WHO (2023) C_WHO

Prompt, effective antimalarial treatment, and supportive care can substantially reduce the rate of mortality from severe malaria. However, many children in malaria-endemic countries do not have access to health facilities or a qualified health care provider and do not receive the necessary care in a... more

Download (298)

View PDF (268)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (120)

View PDF (160)

Leprosy Programme and Transmission Assessment - Tool accompanying the Technical guidance on interruption of transmission and elimination of leprosy

World Health Organization WHO (2023) C_WHO

The Leprosy Programme and Transmission Assessment (LPTA) is an activity that is carried out by internal teams towards the end of Phase 1 (see Leprosy Elimination Framework in the Annex) when a subnational jurisdiction (typically second-tier) reaches the milestone for interruption of transmission, i.... more

Download (256)

View PDF (2320)

Hand Hygiene Observation Form

World Health Organization WHO (2009) C_WHO

Evaluation of hand hygiene practices and related perception and knowledge at a health-care facility is one vital element of the strategy to improve hand hygiene. Continuous monitoring is very helpful in measuring the changes induced by implementation and to ensure that the interventions have been ef... more

Download (165)

View PDF (181)

Aide-mémoire - Schistosomiase (bilharziose)

World Health Organization WHO (2014) C_WHO

La schistosomiase est une parasitose aiguë et chronique provoquée par des vers (trématodes) du genre Schistosoma. Au moins 249 millions de personnes ont eu besoin d’un traitement préventif en 2012. Le traitement préventif, qui doit être répété sur plusieurs années, permettra de réduire ... more

Download (141)

View PDF (189)

Fact Sheet - Lymphatic Filiariasis

World Health Organization WHO (2014) C_WHO

Lymphatic filariasis, commonly known as elephantiasis, is a neglected tropical disease. Infection occurs when filarial parasites are transmitted to humans through mosquitoes. When a mosquito with infective stage larvae bites a person, the parasites are deposited on the person’s skin from where the... more

Download (130)

View PDF (502)

Formation sur le suivi et l’évaluation épidémiologique du traitement médicamenteux de masse pour l’élimination de la filariose lymphatique : guide des apprenants

World Health Organization WHO; Institutional research information sharing iris (2013) C_WHO

Formation sur le suivi et l’évaluation épidémiologique du traitement médicamenteux de masse pour l’élimination de la filariose lymphatique : guide des apprenants. Organisation mondiale de la Santé.

Download (116)

View PDF (373)

Preventable Epilepsy: Taenia Solium Infection Burdens Economies, Societies and Individuals

World Health Organization WHO (2016) C_WHO

Burden of T. solium: Neurocysticercosis is a disease induced by T. solium larvae penetrating human tissues, especially the nervous system. Neurocysticercosis burdens economies, societies and individuals because of the impact of epilepsy on wages, health costs and social stigmatization of sufferers. ... more

Download (274)

View PDF (472)

Guidelines for laboratory and field testing of molluscicides for control of schistosomiasis

World Health Organization WHO (2019) C_WHO

This document provides up-to-date guidance on laboratory studies as well as smallscale (semi-field) and large-scale field trials to assess the efficacy and determine field application rates of new molluscicide products for control of schistosomiasis.

Download (296)

View PDF (321)

Informing vaccination programs: a guide to the design and conduct of dengue serosurveys

World Health Organization WHO (2020) C_WHO

In this document, recommendations are provided on designing and implementing a cross-sectional serosurvey using school-based sampling to estimate age-specific DENV seroprevalence to inform a country’s national dengue vaccination program. The document includes recommendations for methods for ... more

Download (173)

View PDF (802)

Vector alert: Anopheles stephensi invasion and spread in Africa and Sri Lanka

World Health Organization WHO (2023) C_WHO

Anopheles stephensi, a highly competent vector of Plasmodium falciparum and P. vivax, is considered an efficient vector of urban malaria. Until 2011, the reported distribution of An. stephensi was confined to certain countries of South Asia and parts of the Arabian Peninsula. Since then, the vector ... more

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended